13 Results for "

RNA splicing modulator

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "RNA splicing modulator" in MCE Product Catalog:

Cat. No.: HY-150248
CAS No.: 2726461-43-2
Purity:  98.58%
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

RNA splicing modulator 3 is an RNA splicing modulator. RNA splicing modulator 3 modulates nucleic acid splicing, including pre-mRNA splicing .
loading...
    loading...
Cat. No.: HY-150246
CAS No.: 2726461-38-5
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

RNA splicing modulator 1 (compound 233) is a RNA splicing modulator, with an AC50 value of <100 nM .
loading...
    loading...
Cat. No.: HY-177360
CAS No.: 3067915-73-2
Synonyms: RNA splicing modulator-4
Target:  

DNA/RNA Synthesis

Ruxuplam (RNA splicing modulator-4) is an RNA splicing modulator. Ruxuplam controls the inclusion or exclusion of specific exons in precursor mRNA (pre-mRNA) by regulating alternative splicing events, thereby altering the coding sequence and function of mature mRNA. Ruxuplam shows promise for research into neurodegenerative diseases (such as Huntington's disease) and cancers .
loading...
    loading...
Cat. No.: HY-124648
CAS No.: 1446311-56-3
Purity:  98.85%
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .
loading...
    loading...
Cat. No.: HY-150247
CAS No.: 2726461-41-0
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

RNA splicing modulator 2 (compound 256) is a RNA splicing modulator .
loading...
    loading...
Cat. No.: HY-179117
CAS No.: 1340819-53-5
Target:  

DNA/RNA Synthesis

Research Areas:  

Infection

RNA splicing modulator 5 (compound 22) is a small molecule probe that can specifically target the K-turn region of U4/U6 snRNA. RNA splicing modulator 5 can stabilize RNA structure in vitro and inhibit its binding to Snu13 protein (IC50 = 3.2 μM) .
loading...
    loading...
Cat. No.: HY-114461
CAS No.: 147025-57-8
Research Areas:  

Cancer

FD-895 is a spliceosome modulator derived from a polyketide natural product, targeting the SF3b subunit of the spliceosome. FD-895 possesses core biological activities for regulating RNA splicing (intron retention, alternative splicing) and inducing apoptosis of cancer cells. FD-895 can be used for the research of cancer, such as chronic lymphocytic leukemia (CLL) .
loading...
    loading...
Cat. No.: HY-189604
CAS No.: 2927390-43-8
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

RNA splicing modulator 7 is an RNA splicing modulator. RNA splicing modulator 7 modulates mRNA splicing by targeting cis-elements of primary RNA transcripts (such as splice sites, branch points, splicing enhancers, or splicing silencers). RNA splicing modulator 7 has anticancer activity against leukemia .
loading...
    loading...
Cat. No.: HY-W278073
CAS No.: 430443-35-9
Research Areas:  

Infection Cancer

RNA splicing modulator 6 (Compound c7) is a RNA splicing modulator. RNA splicing modulator 6 induces changes in pre-mRNA splicing. RNA splicing modulator 6 causes accumulation of unspliced RNA in the Hs-Hsh155 strain. RNA splicing modulator 6 reduces proliferation of chronic myeloid leukemia cells harboring the cancer-associated SRSF2 P95H mutation .
loading...
    loading...
Cat. No.: HY-148828
CAS No.: 1235945-37-5
Target:  

iGluR

Research Areas:  

Neurological Disease

LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.
loading...
    loading...
Cat. No.: HY-148828A
Target:  

iGluR

Research Areas:  

Neurological Disease

LSP-GR3 sodium is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.
loading...
    loading...
Cat. No.: HY-133895
CAS No.: 1449592-94-2
Target:  

DNA/RNA Synthesis

Research Areas:  

Neurological Disease

SMN-C5 is an inducer of SMN2 exon 7 inclusion. SMN-C5 binds to the SMN2 exon 7 5′-splice site/U1 snRNA helix (Kd = 28 μM) and positively allosterically modulates SMN2 splicing correction. SMN-C5 binds to SMN2 exon 7 ESE2 and partially displaces hnRNP G, enhances the affinity of U1 snRNP for the weak splice site, binds to a bulged adenine in the major groove and forms hydrogen bonds, while not affecting the interaction of Tra2-β1 with ESE2 RNA. SMN-C5 can be used for research on spinal muscular atrophy .
loading...
    loading...
Cat. No.: HY-L248
858 compounds

The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development.

The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

  • 1